Forms of antiviral nucleosides
Novel crystalline forms of molnupiravir, including crystalline Forms I and II, which are crystalline forms of uridine 4-oxime 5′-(2-methylpropanoate), may be useful as antiviral agents, specifically as antiviral treatments for infections caused by Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV), Chikungunya fever virus (CHIK), Ebola virus, influenza virus, respiratory syncytial virus (RSV), Zika virus, and coronaviruses, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and, most recently, SARS-CoV-2 (also known as 2019-nCoV).
1 . Crystalline form of {(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1 (2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate, wherein said crystalline form is characterized by an X-ray powder diffraction pattern containing at least four ° 2θ values measured using CuKα radiation chosen from: about 3.34° 2θ, about 6.53° 2θ, about 13.11° 2θ, about 18.13° 2θ, about 19.51° 2θ, about 19.97° 2θ, and about 21.47° 2θ.
2 . The crystalline form according to claim 1 , wherein said crystalline form has a monoclinic crystal system.
3 . The crystalline form according to claim 1 , wherein said crystalline form is prepared by crystallization from ethyl acetate and MTBE.
4 . The crystalline form according to claim 1 , wherein said crystalline form is prepared by crystallization from acetone and n-heptane vapors.
5 . The crystalline form according to claim 1 , wherein said crystalline form is prepared by crystallization from water.
6 . The crystalline form according to claim 1 , characterized by an X-ray powder diffraction pattern containing ° 2 θ values measured using CuKα radiation at about 3.34° 2θ, about 19.51° 2θ, about 19.97° 2θ, and about 21.47° 2θ.
7 . The crystalline form according to claim 1 , characterized by having an X-ray powder diffraction containing at least five ° 2 θ values measured using CuKα radiation chosen from: about 3.34° 2θ, about 6.53° 2θ, about 13.11° 2θ, about 17.06° 2θ, about 17.33° 2θ, about 18.13° 2θ, about 19.51° 2θ, about 19.97° 2θ, and about 21.47° 2θ.
8 . Crystalline form of {(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1 (2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate, wherein said crystalline form is characterized by an X-ray powder diffraction pattern containing
(a) at least four ° 2θ values measured using CuKα radiation chosen from: about 3.33° 2θ, about 6.61° 2θ, about 9.92° 2θ, about 13.23° 2θ, about 16.51° 2θ, about 17.82° 2θ, about 19.03° 2θ, about 22.10° 2θ, and about 23.85° 2θ; or
(b) at least four ° 2θ values measured using CuKα radiation chosen from: about 17.7° 2θ, about 18.2° 2θ, about 18.9° 2θ, about 21.0° 2θ, and about 22.0° 2θ.
9 . The crystalline form according to claim 8 , wherein said crystalline form is prepared by crystallization from acetone and n-heptane.
10 . The crystalline form according to claim 8 , characterized by an X-ray powder diffraction pattern containing ° 2θ values measured using CuKα radiation at: about 3.33° 2θ, about 17.82° 2θ, about 19.03° 2θ, and about 22.10° 2θ.
11 . The crystalline form according to claim 8 , characterized by an X-ray powder diffraction pattern containing at least five ° 2θ values measured using CuKα radiation chosen from: about 3.33° 2θ, about 6.61° 2θ, about 9.92° 2θ, about 13.23° 2θ, about 16.51° 2θ, about 17.82° 2θ, about 19.03° 2θ, about 22.10° 2θ, and about 23.85° 2θ.
12 . A pharmaceutical composition comprising the crystalline form according to claim 1 and a pharmaceutically acceptable carrier.
13 . The pharmaceutical composition according to claim 12 , wherein the pharmaceutical composition is a solid dosage form for oral administration.
14 . A pharmaceutical composition comprising the crystalline form according to claim 8 and a pharmaceutically acceptable carrier.
15 . The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition is a solid dosage form for oral administration.
16 . A method of inducing an antiviral response in a subject in need thereof comprising administering the crystalline form according to claim 1 to the subject.
17 . The method according to claim 16 , wherein the subject has SARS-COV-2.
18 . A method of inducing an antiviral response in a subject in need thereof comprising administering the crystalline form according to claim 8 to the subject.
19 . The method according to claim 18 , wherein the subject has SARS-COV-2.